A Phase 2 Study of Lenalidomide, Rituximab, Cyclophosphamide and Dexamethasone (LR-CD) for Untreated Low Grade Non-Hodgkin Lymphoma Requiring Therapy

Trial Profile

A Phase 2 Study of Lenalidomide, Rituximab, Cyclophosphamide and Dexamethasone (LR-CD) for Untreated Low Grade Non-Hodgkin Lymphoma Requiring Therapy

Completed
Phase of Trial: Phase II

Latest Information Update: 01 May 2017

At a glance

  • Drugs Lenalidomide (Primary) ; Cyclophosphamide; Dexamethasone; Rituximab
  • Indications B cell lymphoma; Chronic lymphocytic leukaemia; Follicular lymphoma; Lymphoma; Non-Hodgkin's lymphoma; Waldenstrom's macroglobulinaemia
  • Focus Therapeutic Use
  • Most Recent Events

    • 05 Feb 2016 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
    • 10 Dec 2013 Results for Waldenstrom's macroglobulinemia cohort presented at the 55th Annual Meeting and Exposition of the American Society of Hematology.
    • 27 Mar 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top